top of page

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Clinicaltrials.gov ID

NCT05123482

Status

Recruiting

Study Type

Interventional, Phase 1/2

Sponsor

AstraZeneca

Start Date

October 18, 2021

Anticipated End Date

June 30, 2025

Study Contact

Name: AstraZeneca Clinical Study Information Center

Phone Number:1-877-240-9479

Email: information.center@astrazeneca.com

About the Study

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours

Conditions

  • Breast Cancer

  • Biliary Tract Carcinoma

  • Ovarian Cancer

  • Endometrial Cancer

Inclusion/Exclusion Criteria?

Primary, Secondary, Other Outcome Measures??

Locations in Canada

  • Foothills Medical Centre, Calgary, Alberta, T2N 4N2, Canada

  • BC Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada

  • The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada

  • Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada

  • McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada

Apply Now

About the Study

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours

Conditions

  • Breast Cancer

  • Biliary Tract Carcinoma

  • Ovarian Cancer

  • Endometrial Cancer

Interventions

DRUG:

  • AZD8205


Locations in Canada

  • Foothills Medical Centre, Calgary, Alberta, T2N 4N2, Canada

  • BC Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada

  • The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada

  • Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada

  • McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada

bottom of page